Brighton Jones LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,641 shares of the medical research company’s stock after selling 1 shares during the quarter. Brighton Jones LLC’s holdings in Amgen were worth $455,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Financial Advisory Service Inc. grew its stake in shares of Amgen by 0.3% during the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after buying an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC grew its stake in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after purchasing an additional 7 shares in the last quarter. Ballentine Partners LLC grew its stake in Amgen by 0.3% in the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after purchasing an additional 9 shares in the last quarter. Hudock Capital Group LLC grew its stake in Amgen by 0.5% in the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after purchasing an additional 10 shares in the last quarter. Finally, Investment Partners Ltd. OH ADV grew its stake in Amgen by 0.5% in the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock worth $377,000 after purchasing an additional 11 shares in the last quarter. 78.20% of the stock is currently owned by institutional investors.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at approximately $9,888,326.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,239,673 over the last 90 days. Insiders own 0.19% of the company’s stock.

Shares of Amgen Inc. (AMGN) opened at $170.13 on Wednesday. Amgen Inc. has a 12-month low of $138.83 and a 12-month high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The company has a market capitalization of $124,493.66, a PE ratio of 13.63, a PEG ratio of 2.48 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. During the same period last year, the firm earned $3.02 EPS. The company’s quarterly revenue was down .7% on a year-over-year basis. analysts predict that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.

Amgen declared that its board has authorized a share buyback program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is presently 41.63%.

A number of analysts have weighed in on AMGN shares. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 target price (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 26th. Mizuho restated a “buy” rating and set a $198.00 target price (up previously from $183.00) on shares of Amgen in a report on Thursday, September 28th. Argus upped their target price on Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Deutsche Bank AG restated a “hold” rating and set a $174.00 target price (up previously from $172.00) on shares of Amgen in a report on Wednesday, July 26th. Thirteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Amgen presently has a consensus rating of “Buy” and an average target price of $190.03.

COPYRIGHT VIOLATION NOTICE: “Brighton Jones LLC Has $455,000 Holdings in Amgen Inc. (AMGN)” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/15/brighton-jones-llc-has-455000-holdings-in-amgen-inc-amgn-2.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.